NAUT Nautilus Biotechnology, Inc. Insider Trading

AH Equity Partners BIO II, LLC sells 5,000,000 shares at $2.35, reducing stake by 83.7%, leaving 971,885 shares

AH Equity Partners BIO II, LLC, a 10% owner, executed 2 separate sales totaling 5,000,000 shares for $11,750,000.00 on 2026-06-02 at a blended average price of $2.35. This reduction decreased the filer's holdings from 5,971,885 shares to 971,885 shares, representing a -83.7% net change in pre-transaction holdings. The sales occurred at $2.35 while the current price stands at $2.68, and notably, the company reported a full-year net income of $-14,697,000.00, indicating material operating losses. The magnitude of this exit—reducing a substantial ownership position to a minimal stake—combined with the company's unprofitable financial profile, suggests a significant repositioning by a major shareholder.

CEO Sujal M Patel buys 25,000 NAUT shares at $2.61; mixed track record at this ticker.

CEO Sujal M Patel purchased 25,000 shares at $2.61, increasing holdings from 10,341,721 to 10,366,721 shares. His prior trades at NAUT show highly inconsistent outcomes: two September 2025 buys generated 90-day returns of +197.2% and +207.0%, but two March 2025 buys delivered -29.1% and -29.6%, with only 2 of 5 prior buys at this ticker proving well-timed at the 90-day mark. The company remains unprofitable with net income of $-13.6M over its most recent fiscal year. The stock is trading at $2.62, down 9.3% from its 52-week high of $2.89, though up 30.4% over the past 30 days and 26.6% over 90 days, placing this buy during a period of recent strength rather than a depressed entry point. The bifurcated timing history at NAUT—spectacular wins paired with significant losses—makes this purchase difficult to characterize as driven by consistent conviction.

CMO Suzuki Kentaro buys initial 4,000 shares of NAUT at $1.49; stock up 95.2% in 30 days despite $-13.6M net loss

Suzuki Kentaro, Chief Marketing Officer, made his first purchase of Nautilus Biotechnology shares, acquiring 4,000 shares at $1.49 on 2025-11-06, establishing a new position from zero prior holdings. The transaction occurs within a volatile price environment: the stock has appreciated 95.2% over the past 30 days and 132.8% over 90 days, yet remains 42.6% below its 52-week high of $2.89 and trades at $1.66 currently. Notably, the company reported a full-year net income of $-13.6M, indicating persistent unprofitability. The purchase timing coincides with a significant recent rally rather than accumulation during depressed valuations, warranting consideration of whether this reflects management confidence or participation in momentum-driven movement.

CEO Sujal M Patel buys 200,000 shares at blended $0.68 after stock falls 78.2% from 52-week high.

Patel Sujal M executed 2 separate open-market purchases totaling 200,000 shares for $135,574.80 on 2025-09-05 and 2025-09-08, increasing his holdings by 2.0% to 10,341,721 shares. The timing is notable: the stock trades at $0.67 current price, down 78.2% from the 52-week high of $3.08 and down 8.3% over the prior 30 days. However, Patel's prior trades at NAUT show a consistent pattern of poor timing—0 of 5 prior buys achieved positive 90-day returns, with most recent March 2025 purchases showing -24.1% and -23.8% 30-day losses respectively. The company's fundamentals remain challenging, posting a net loss of $15,033,000 on a market cap of $84,624,431.74, providing limited context for why accumulated holdings now exceed 10.3M shares at severely depressed valuations.

General Counsel Murphy buys 20,000 shares at $0.64; holds 74,140 post-buy as stock down 78.6% from 52-week high

Matthew B. Murphy, General Counsel, purchased 20,000 shares of NAUT at $0.64, increasing his holdings by 36.9% to 74,140 shares. The timing is notable: the stock is trading at $0.66, down 78.6% from its 52-week high of $3.08, and the company posted net income of $-15,033,000.00 over its most recent full fiscal year. An insider purchase of this magnitude during significant price decline and continuing losses warrants investor attention to the motivations and timing, particularly given the 16.2% deterioration in the prior 30 days alone.

CFO Mowry purchases 15,000 shares of NAUT at $0.77; stock -76.3% from 52-week high, company unprofitable

CFO and Treasurer Anna Mowry purchased 15,000 shares at $0.77 on 2025-05-29, increasing her holdings by 22.1% to 83,000 shares total. The transaction occurs against a backdrop of significant distress: Nautilus Biotechnology reported net income of $-16,613,000.00 in its most recent full fiscal year, and the stock trades at $0.73, representing a -76.3% decline from its 52-week high of $3.08. The purchase at $0.77 represents the CFO's open-market acquisition of equity during a period of substantial operational losses and depressed valuation relative to recent history. Investors should note the wide variance between transaction price ($0.77) and current price ($0.73), as well as the 90-day decline of -39.7%, suggesting continued deterioration in market confidence.

Chief Scientist Parag Mallick purchases 13,500 shares totaling $9,885.15 across 2 transactions at $0.73 as NAUT stock trades 76.6% below 52-week high.

Mallick Parag, Chief Scientist, executed 2 separate purchases totaling 13,500 shares for $9,885.15 at $0.73 per share on 2025-05-08 and 2025-05-12. This adds 13,500 shares to his existing 20.48M-share position—a modest 0.1% increase in holdings. The transactions occurred while the stock trades 76.6% below its 52-week high of $3.08 and down 9.0% over 30 days and 55.0% over 90 days. The company reported a net loss of $16,613,000.00 for its most recent full fiscal year, indicating ongoing unprofitability. An insider purchase during a period of both depressed absolute price and recent momentum decline, coupled with negative earnings, presents a mixed signal that warrants context around the motivations and broader capital deployment strategy.

CEO Sujal M Patel buys 77,233 shares (77.2K) at blended $1.00; stock down 67.9% from 52-week high; unprofitable company.

CEO Sujal M Patel executed 2 separate purchases totaling 77,233 shares for $76,918.09 on 2025-03-19 and 2025-03-20, acquiring shares at $0.99 and $1.00 respectively. At current price of $0.99, the stock is down 67.9% from its 52-week high of $3.08 and has fallen 40.7% over the past 30 days and 43.8% over 90 days. His prior trade history at NAUT shows 5 preceding buys, of which only 1 (20% win rate) achieved positive 90-day returns; the remaining four buys resulted in declines ranging from 0.2% to 10.7% over 90 days. Nautilus Biotechnology reported negative net income of $16,446,000 over its most recent full fiscal year, indicating ongoing unprofitability despite the CEO's accumulation activity.